Suppr超能文献

在使用特定抗精神病药物治疗且以阴性或思维紊乱症状突出的精神分裂症门诊患者中,PANSS 阴性症状因子评分的可靠性、有效性和变化检测能力。

Reliability, validity and ability to detect change of the PANSS negative symptom factor score in outpatients with schizophrenia on select antipsychotics and with prominent negative or disorganized thought symptoms.

机构信息

Roche Products Ltd., 6 Falcon Way, Shire Park, Welwyn Garden City AL7 1TW, United Kingdom.

F. Hoffmann-La Roche Ltd., Basel, Switzerland.

出版信息

Psychiatry Res. 2014 Aug 15;218(1-2):219-24. doi: 10.1016/j.psychres.2014.04.009. Epub 2014 Apr 13.

Abstract

The PANSS is a valid instrument assessing schizophrenia symptom severity. Analyses have identified a five-factor solution. The negative symptom factor (NSFS) is robust, having been replicated in multiple analyses. The score has superior content validity versus the negative subscale. Aspects of validity in patients with predominant negative symptoms have yet to be established. The present data are from a Phase IIb study of add-on bitopertin therapy in schizophrenia outpatients with prominent negative or disorganized thought symptoms treated with antipsychotics. Analyses were conducted to evaluate reliability, validity and sensitivity to change. Test-retest screening to baseline was high (ICC=0.93). This was maintained in-study, for patients with no change in CGI negative symptom severity (CGI-S-N). Internal consistency at baseline was adequate (α=0.71) and increased at later assessments. Pearson correlation at baseline showed a good association between NSFS and CGI-S-N (0.63), but not overall CGI-S (0.31). Association with PSP at baseline was moderate (-0.39) and for change at Week eight good (-0.65). NSFS responders (≥20% improvement) at Week eight showed a significant improvement in function. The analyses demonstrated reliability, validity and ability to detect change of the NSFS, in schizophrenia patients with prominent negative or disorganized thought symptoms.

摘要

PANSS 是一种评估精神分裂症症状严重程度的有效工具。分析已经确定了一个五因素解决方案。阴性症状因子(NSFS)是稳健的,在多项分析中得到了验证。与阴性子量表相比,该评分具有更高的内容效度。在以阴性症状为主的患者中,其有效性的各个方面尚未得到确定。本数据来自于一项针对伴有突出阴性或思维紊乱症状的精神分裂症门诊患者的附加双氢麦角隐亭治疗的 IIb 期研究,这些患者接受了抗精神病药物治疗。进行了分析以评估可靠性、有效性和对变化的敏感性。从测试到测试的筛选到基线很高(ICC=0.93)。在研究期间保持不变,对于 CGI 阴性症状严重程度无变化的患者(CGI-S-N)。基线时的内部一致性足够(α=0.71),并且在以后的评估中增加。基线时 NSFS 与 CGI-S-N 之间存在良好的相关性(0.63),但与总体 CGI-S 相关性不高(0.31)。与 PSP 基线的相关性为中度(-0.39),而第八周的变化相关性良好(-0.65)。第八周时 NSFS 应答者(≥20%改善)的功能显著改善。这些分析表明,在伴有突出阴性或思维紊乱症状的精神分裂症患者中,NSFS 具有可靠性、有效性和检测变化的能力。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验